Search results
'An Officer and a Gentleman' actor Louis Gossett Jr. died from COPD, report says: What to know about...
Yahoo Canada Style· 5 hours agoContact a qualified medical professional before engaging in any physical activity, or making any...
Earnings call: Regeneron reports steady growth, prepares for new launches By Investing.com
Investing.com· 3 hours agoThis growth was primarily driven by strong sales of Dupixent and Libtayo, as well as collaboration...
'An Officer and a Gentleman' actor Louis Gossett Jr.'s cause of death revealed
USA TODAY via Yahoo News· 2 days agoCOPD consists of a group of diseases that cause breathing-related problems and airflow blockage,...
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 5 hours agoRegeneron stock is forming a flat base with a buy point at 998.33, according to MarketSurge. That's...
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
WFRV 5 Green Bay· 2 days agoSociety (ATS) 2024 International Conference taking place May 12-22 in San Diego. "We look forward to presenting encouraging data from our Phase 2a COURSE trial in COPD with ...
AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval
Pharmaceutical Technology via Yahoo Finance· 3 days agoAccording to leading data and analytics company GlobalData’s Sales and Forecast database, total...
Earnings call: Pulmonx sees 30% sales boost in Q1, eyes $84M annual target By Investing.com
Investing.com· 14 hours agoThe medical device company, which specializes in treatments for chronic obstructive pulmonary...
Your Health: The connection between inflammation and poverty
WJET - WFXP Erie· 3 hours agoDiabetes, cardiovascular disease, arthritis, allergies and COPD — all are life-threatening...
Lawsuit accuses Boehringer Ingelheim of false patent listings
Hartford Business Journal· 10 hours agoThe named defendants in the lawsuit are Boehringer Ingelheim Pharmaceuticals Inc., based in...
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
Motley Fool via Yahoo Finance· 14 hours agoA high-dose formulation, Eylea hit the market last year. The new approval grants patients the luxury...